Teach me lithium as a whole…history pharmacokinetics dynamics steady state level half life pharmacodynamics indications side effects moa drug interactions toxicity side effects common serious rare contraindications precautions discontinuation absorption dosage formulation routes guidelines … nice apa cpg synopsis
Reading File
Finding Sources
Finding Sources
Searching PubMed
"lithium"[MeSH Terms] AND "bipolar disorder"[MeSH Terms] AND guideline
Now let me read the key lithium sections from the most comprehensive sources — Katzung, Goodman & Gilman, Maudsley, Stahl's, and Kaplan & Sadock — in parallel:
Reading File
Reading File
Reading File
Searching PubMed
"lithium" AND "bipolar disorder" AND guideline
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Searching the Web
lithium bipolar disorder CANMAT BAP 2023 2024 guidelines clinical practice
Now I have comprehensive data. Let me synthesize the complete lithium monograph:
⚡ LITHIUM — Complete Clinical Monograph
1. HISTORY
Lithium (Li⁺) has one of the most storied histories in psychopharmacology. The element was discovered in 1817, and in the 19th century, lithium salts were widely (and incorrectly) touted as treatments for gout, epilepsy, and "brain diseases." It fell into disrepute — most notably after deaths from cardiac toxicity when lithium chloride was used as a table salt substitute in the 1940s.
The modern era began in 1949, when Australian psychiatrist John Frederick Joseph Cade published a landmark paper reporting that lithium carbonate calmed guinea pigs and subsequently produced dramatic improvement in 10 manic patients. This is widely considered the founding moment of modern psychopharmacology. Danish psychiatrist Mogens Schou confirmed and expanded Cade's work with controlled trials during the 1950s–60s. Despite fierce resistance, lithium was approved in the United States in 1970 for the treatment of acute mania — becoming one of the only drugs approved for a psychiatric disorder until that decade. It remains to this day the only drug proven to reduce suicidality in mood disorders.
2. CHEMISTRY & FORMULATIONS
Lithium (atomic number 3) is the lightest alkali metal (Group IA). It has no known physiological role. Its ionic behavior resembles Na⁺ and K⁺ but it is not a substrate for the Na⁺/K⁺-ATPase pump, meaning it cannot maintain membrane potential.
Available salts:
| Formulation | Elemental Lithium | Notes |
|---|---|---|
| Lithium carbonate 300 mg cap/tab | ~8.1 mmol Li | Most widely used; IR and CR/ER forms |
| Lithium carbonate 400 mg tab | 10.8 mmol Li | Common UK formulation (Priadel, Camcolit) |
| Lithium carbonate 450 mg (extended-release) | ~12.2 mmol Li | Eskalith CR, Lithobid |
| Lithium citrate liquid 300 mg/5 mL | ~8.1 mmol/5 mL | For patients unable to swallow tablets |
| Lithium citrate 5.4 mmol/5 mL | ≡ 200 mg carbonate | UK liquid — specify strength carefully |
| Lithium citrate 10.8 mmol/5 mL | ≡ 400 mg carbonate | UK liquid — specify strength carefully |
⚠️ Caution: Liquid preparations must specify concentration explicitly — dosing errors between the two liquid strengths can cause sub-therapeutic dosing or toxicity. Liquids must be given 12-hourly.
Routes: Oral only (IV preparations exist only in research contexts).
3. PHARMACOKINETICS
(Katzung's Basic and Clinical Pharmacology, 16th ed., Table 29-5; Goodman & Gilman's, 13th ed.)
| Parameter | Detail |
|---|---|
| Absorption | Virtually complete; standard release absorbed within 6–8 h; peak plasma 30 min–2 h (IR), 4–5 h (CR) |
| Bioavailability | ~100% (complete GI absorption) |
| Distribution | Total body water; no protein binding; Vd = 0.5 L/kg initially, rising to 0.7–0.9 L/kg at steady state; some sequestration in bone; slow entry into CNS/intracellular compartment |
| Protein binding | None |
| Metabolism | None — not metabolized |
| Elimination | Virtually entirely renal; glomerular filtration then ~80% reabsorbed proximally (competes with Na⁺); Li⁺ clearance ≈ 20% of creatinine clearance |
| Half-life | ~20–24 h in healthy adults; 24–36 h in patients in their 70s; shorter in children (higher GFR) |
| Steady state | Reached in ~5 half-lives = 4–5 days in adults; 5+ days in elderly |
| Renal handling | Proximal tubule reabsorption is the critical determinant — any state that promotes Na⁺ depletion causes compensatory Li⁺ reabsorption, raising serum levels |
Steady-state serum Li⁺ levels are achieved after five half-lives. In the elderly (t½ ~30 h), this means 5–7 days. Dose adjustments must account for this delay.
4. MECHANISM OF ACTION (MOA)
The precise mechanism remains incompletely understood, but several well-characterized molecular actions are established:
A. Inositol Depletion (Phosphoinositide Signaling)
Li⁺ inhibits inositol monophosphatase (IMPase) and other enzymes involved in the recycling of membrane phosphoinositides, blocking the conversion of inositol phosphates back to free inositol. This depletes intracellular inositol, reducing signaling via IP₃ and diacylglycerol (DAG) — second messengers for α-adrenergic and muscarinic transmission. This "inositol depletion hypothesis" is also shared by valproate (via a different mechanism) and carbamazepine.
B. GSK-3 Inhibition (Glycogen Synthase Kinase-3)
Li⁺ directly inhibits GSK-3β, a multifunctional serine-threonine kinase involved in:
- Insulin/IGF signaling
- BDNF signaling
- Wnt/β-catenin pathway — Li⁺ inhibits GSK-3β → reduced phosphorylation of β-catenin → β-catenin accumulates and translocates to nucleus → transcription of neuroprotective and neuroplasticity proteins
- This is also the mechanism underlying Li⁺-induced nephrogenic diabetes insipidus (GSK-3β inhibition in renal distal tubule → vasopressin insensitivity → aquaporin-2 downregulation)
C. Ion Transport
- Can substitute for Na⁺ in generating a single action potential but is not a substrate for the Na⁺/K⁺-ATPase pump — cannot maintain membrane potential
- Develops a relatively small gradient across biological membranes
- Has 1.5–2.0× greater affinity than Na⁺ for ENaC (epithelial Na⁺ channel) in distal tubules
D. Monoamine Effects
- Modest effects on monoamine receptors
- Enhances serotonergic neurotransmission (basis for augmentation in depression)
- Reduces dopamine receptor sensitivity over time (antimanic effect)
E. Neuroprotection
- Long-term Li⁺ use associated with 50% reduced dementia risk emerging with as little as 301–365 days of treatment
- Stimulates proliferation of pluripotent stem cells
- Increases BDNF levels
- Inhibits apoptosis pathways
5. PHARMACODYNAMICS
Therapeutic concentrations of Li⁺ (0.5–1.0 mEq/L) have almost no discernible psychotropic effects in individuals without psychiatric symptoms. Unlike most psychotropics, Li⁺ produces no sedation and has no significant antagonism of autonomic or CNS receptors. Its therapeutic effects emerge gradually over days to weeks, consistent with its downstream gene-regulatory and neuroprotective mechanisms rather than acute receptor blockade.
6. THERAPEUTIC DRUG MONITORING — TARGET LEVELS & STEADY STATE
(Goodman & Gilman's Table 19-6; Maudsley 15th ed.)
| Indication | Target Serum Level (12-h trough) |
|---|---|
| Acute mania | 1.0–1.5 mEq/L |
| Outpatient acute mania | Never exceed 1.2 mEq/L (levels >1.2 increase long-term renal insufficiency risk by 74%) |
| Prophylaxis / maintenance (bipolar) | 0.6–1.0 mEq/L |
| Difficult-to-treat or breakthrough mania | Upper end: 0.8–1.0 mEq/L |
| Antidepressant augmentation (unipolar) | 0.4–0.6 mEq/L |
| Geriatric patients | 0.6–0.8 mEq/L (lower target) |
Sampling: Always measure 12 hours after the last dose (morning trough, 12-h post-dose sample). Measurement at other times gives falsely elevated or misleading values.
7. DOSING & TITRATION
(Maudsley 15th ed.; Goodman & Gilman; Harriet Lane)
Adults
- Start: 400 mg at night (lithium carbonate); can start at 200–300 mg twice daily
- Check plasma level at 7 days, then 7 days after each dose change
- Titrate upward guided by levels and clinical response
- Typical maintenance dose: 900–1200 mg/day in divided doses (varies by formulation)
- Extended-release loading for acute mania: Three 10 mg/kg doses at 4 PM, 6 PM, 8 PM; then lithium carbonate once nightly from day 2
Elderly
- Start: 200 mg at night (lower starting dose due to reduced renal clearance)
- Target lower serum levels: 0.6–0.8 mEq/L
- Increased risk of toxicity — more frequent monitoring required
Children (≥12 years, FDA-approved; 6–12 off-label)
- Higher Vd and GFR → shorter t½ → may need higher mg/kg doses and multiple daily dosing
- Ages 6–12: ~30 mg/kg/day in 3 divided doses → Li⁺ ~0.6–1.2 mEq/L in 5 days
- Monitor renal and thyroid function as in adults
Dosing Frequency
- Once nightly preferred for maintenance — reduces polyuria risk
- Twice daily for liquids (bioavailability considerations) and during acute phase
- Extended-release forms can improve tolerability
8. INDICATIONS
FDA-Approved
- Acute treatment of manic episodes in bipolar I disorder (adults and ≥12 years)
- Maintenance therapy for bipolar disorder (prophylaxis of manic and depressive episodes)
Evidence-Based Off-Label
- Bipolar depression (monotherapy or adjunctive)
- Augmentation of antidepressants in treatment-resistant unipolar depression (Level A evidence; meta-analyses confirmed benefit)
- Recurrent unipolar depression prophylaxis
- Schizoaffective disorder (adjunctive)
- Aggression / impulse dyscontrol (reduces aggression across many diagnoses)
- Cluster headache prophylaxis
- Suicidality reduction — the only drug proven to reduce suicide risk across mood disorders (both unipolar and bipolar); database studies show dose-response relationship
- Neutropenia / leukopenia (stimulates granulopoiesis — used in clozapine-induced neutropenia)
- Emerging: Alzheimer's disease, Parkinson's disease, ALS, and other neurodegenerative conditions (neuroprotective data)
CPG Positioning (Major International Guidelines)
All major guidelines — APA, CANMAT, BAP, NICE, WFSBP, RANZCP, ISBD — recommend:
- First-line monotherapy for bipolar prophylaxis/maintenance
- First-line monotherapy for acute mania (RANZCP, CANMAT)
- First-line for mild-moderate acute mania (APA, BAP)
- First-line combination for severe or mixed mania (APA)
- The 2023 CANMAT/ISBD update reaffirms lithium as first-line maintenance across bipolar subtypes
9. SIDE EFFECTS
9A. Common (Dose-Related, Predictable)
| System | Side Effect | Management |
|---|---|---|
| Neurological | Fine postural tremor (15–70%) | Propranolol; reduce dose; avoid caffeine |
| Renal | Polyuria / polydipsia (60%) — nephrogenic DI | Once-daily dosing; amiloride (blocks ENaC) |
| GI | Nausea, diarrhea, vomiting (especially on initiation) | Take with food; use CR formulation |
| Cognitive | Dulling, memory impairment, mental slowing | Dose reduction; once-nightly dosing |
| Weight | Weight gain | Diet, metformin consideration |
| Metabolic | Metallic taste in mouth | Usually tolerable |
| Skin | Ankle edema | — |
| Hematologic | Benign leukocytosis (PMN count up to 12,000–15,000) | No treatment needed; can be useful in clozapine-induced agranulocytosis |
9B. Long-Term / Serious
| System | Effect | Notes |
|---|---|---|
| Thyroid | Hypothyroidism (7–10% overt; 23% subclinical); women have 3–9× higher risk; may occur in up to 20% of middle-aged women; rarely hyperthyroidism | Treat with levothyroxine — not a reason to stop Li⁺; monitor TSH q6 months |
| Renal | Nephrogenic DI; reduced GFR; chronic interstitial nephritis; CKD (especially after >15 years) | eGFR q6 months; stop if eGFR <50 mL/min |
| Parathyroid | Hyperparathyroidism → hypercalcemia (~4–10%); → renal stones, osteoporosis, hypertension | Monitor serum Ca²⁺; surgical referral if symptomatic |
| Cardiac | T-wave flattening/inversion (benign at therapeutic levels); sinus node dysfunction; bradycardia; may unmask Brugada syndrome | Baseline ECG in >60 y, cardiac hx |
| Teratogenicity | Ebstein anomaly (modest increased risk); neonatal toxicity (hypotonia, goiter, "floppy baby") | Avoid in first trimester if possible; fetal echo if continued |
9C. Dermatologic (Common)
- Worsening of acne and psoriasis (often treatable with topicals)
- Alopecia (10–12%; also with VPA) — try selenium/zinc supplements; minoxidil
- Folliculitis, dermatitis, vasculitis (rare)
9D. Rare/Unusual
- Sinus node dysfunction (can occur at therapeutic levels)
- Post-ECT confusion (Li⁺ usually tapered before ECT)
- Seizures in non-epileptic patients at therapeutic levels (rare)
- Brugada syndrome unmasking (≤0.5%)
- Irreversible cerebellar syndrome after severe toxicity
10. TOXICITY
(Maudsley 15th ed.; Goodman & Gilman; Tintinalli)
Toxicity Thresholds
| Serum Level | Presentation |
|---|---|
| 1.5–2.0 mEq/L | Mild toxicity: coarse tremor, nausea, diarrhea, vomiting, slurred speech, drowsiness, muscle weakness |
| 2.0–2.5 mEq/L | Moderate: Confusion, agitation, ataxia, rigidity, myoclonic twitching |
| >2.5 mEq/L | Severe: Delirium, seizures, cardiovascular instability, hyperreflexia, coma |
| >3.0 mEq/L | Life-threatening: Coma, cardiovascular collapse, death |
Key toxicity thresholds:
- Complete recovery common with maximum level ≤2.5 mEq/L
- Permanent neurological sequelae common with mean peak ≥3.2 mEq/L
- Death associated with mean maximum levels of 4.2 mEq/L
⚠️ Serum levels do not always correlate with clinical toxicity — CNS Li⁺ rises more slowly than plasma. Chronic toxicity can be clinically severe despite moderate serum levels. Brain Li⁺ may not be reflected by plasma concentration.
Risk Factors for Toxicity
- Low-salt diet
- Dehydration (fever, diarrhea, hot weather, excessive sweating)
- Drug interactions (NSAIDs, thiazides, ACE inhibitors, ARBs)
- Renal impairment
- Addison's disease (rare)
- Changes in sodium balance
Treatment of Lithium Intoxication
- No specific antidote
- Supportive care; continuous cardiac monitoring; intubation if needed
- Ensure no Na⁺/water depletion — IV normal saline
- Levels 1.5–2.0 mEq/L (asymptomatic): IV saline hydration, monitor serial levels
- Levels >2.0 mEq/L (symptomatic): Hospital admission, medical management
- Osmotic or forced alkaline diuresis for moderate toxicity
- Hemodialysis indications:
- Li⁺ level ≥5.2 mEq/L, OR
- Serum creatinine ≥2.26 mg/dL
- Clinically severe symptoms regardless of level
- Peritoneal dialysis as alternative above 3 mmol/L
- Check levels every 2–4 h until peak (especially with CR formulations — peak may be delayed)
11. DRUG INTERACTIONS
(Maudsley 15th ed., Table 2.2; Goodman & Gilman)
Core mechanism: Any drug that depletes Na⁺ or water causes compensatory proximal tubular reabsorption of Li⁺, raising serum levels and risk of toxicity.
| Drug Class | Effect | Risk / Action |
|---|---|---|
| Thiazide diuretics | ↑ Li⁺ levels by 25–400%; apparent within 10 days | Avoid if possible — highest risk among diuretics |
| ACE inhibitors | ↑ Li⁺ levels (unpredictable, up to 4-fold); develops over weeks; 7× hospitalization risk in elderly | Check Li⁺ level 1 week after initiation; lisinopril contraindicated (100% renally cleared — positive feedback loop) |
| ARBs (losartan, valsartan, etc.) | Similar mechanism to ACEi; ↑ Li⁺ levels | Monitor closely |
| NSAIDs / COX-2 inhibitors | Inhibit renal prostaglandins → ↑ Li⁺ reabsorption; 10% to >400% increase; variable onset | Monitor closely; indomethacin highest risk; aspirin and sulindac least risk; OTC availability increases danger |
| Loop diuretics (furosemide) | ~20% ↓ clearance in healthy adults; greater risk in elderly or volume-depleted patients | Preferred diuretic if needed; watch elderly closely |
| Amiloride | Blocks ENaC → reduces Li⁺ uptake in distal tubule | Useful therapeutically to manage Li⁺-induced NDI; monitor Na⁺ |
| Carbamazepine | Rare neurotoxicity; also causes hyponatremia → Li⁺ retention | Monitor; neurotoxicity possible even at therapeutic levels |
| SSRIs | Can cause hyponatremia → Li⁺ retention; rare CNS toxicity reports | Monitor |
| Antipsychotics | Rare neurotoxicity with haloperidol (historical); EPS sensitization | Historical concern, usually manageable |
| Caffeine | Increases Li⁺ clearance (increased renal excretion); caffeine withdrawal can raise Li⁺ levels | Advise consistent caffeine intake |
| Theophylline | Increases Li⁺ renal clearance → lower levels | Monitor |
| Sodium intake | Low-Na diet → ↑ Li⁺ reabsorption → toxicity | Maintain consistent dietary Na⁺ |
12. CONTRAINDICATIONS
Absolute
- Severe renal impairment (eGFR <30 mL/min) — Li⁺ cannot be cleared safely
- Brugada syndrome (Li⁺ may unmask or worsen)
- Severe cardiac disease with rhythm instability
Relative / Use With Caution
- eGFR 30–50 mL/min — reassess benefit/risk; use lower targets; consider alternatives
- Pregnancy (especially first trimester) — Ebstein anomaly risk; requires fetal cardiac screening if continued
- Breastfeeding — Li⁺ passes freely into breast milk; risk to neonate
- Addison's disease (impaired Na⁺ handling)
- Sodium-depleting states: low-Na diet, excessive sweating, febrile illness
- Significant thyroid disease (not absolute, but requires closer monitoring)
- Children under 12 (off-label; careful monitoring required)
13. PRECAUTIONS
- Establish consistent dietary sodium intake — fluctuations directly affect Li⁺ levels
- Maintain adequate hydration; increase monitoring during febrile illness, heat, diarrhea, vomiting
- Patient education at initiation about toxicity symptoms and risk factors (especially drug interactions, dehydration, OTC NSAIDs) — reinforce at follow-up visits
- Pregnancy: Women of childbearing age need reliable contraception; discuss risk/benefit before continuing in pregnancy; perform fetal echocardiogram if exposure occurs in first trimester
- Postpartum: Withhold for 24–48 h before delivery (post-delivery diuresis can cause sharp rise in maternal Li⁺ levels); restart with close monitoring postpartum
- Surgical procedures: Alert surgical team; hold Li⁺ if patient will be NPO or have major fluid shifts
14. PRE-TREATMENT WORKUP
Before prescribing lithium, obtain:
- Renal: eGFR, urea, electrolytes (including calcium)
- Thyroid: TFTs (TSH, free T4)
- Cardiac: ECG — recommended in patients with cardiovascular risk factors or existing disease; mandatory if considering in patient >60 y
- Baseline weight / BMI
- Pregnancy test in women of childbearing age
- Consider thyroid autoantibodies in middle-aged women (higher risk of Li⁺-induced hypothyroidism)
15. ON-TREATMENT MONITORING
(Maudsley 15th ed., Table 2.1; NICE; CANMAT)
| Parameter | Frequency |
|---|---|
| Serum Li⁺ (12-h trough) | At 7 days after initiation, then 7 days after every dose change, then every 6 months stable |
| eGFR + U&Es + Ca²⁺ | Every 6 months |
| TFTs (TSH) | Every 6 months |
| Weight / BMI | Every visit / every 6 months |
| ECG | At baseline; repeat if symptoms develop or in elderly |
More frequent monitoring required in:
- Patients on interacting drugs (NSAIDs, ACEi, diuretics)
- Elderly patients
- Established chronic kidney disease
- Febrile illness, dehydration, or other fluid-balance disruption
16. DISCONTINUATION
(Maudsley 15th ed.)
Lithium discontinuation carries a substantial and underappreciated risk of rebound mania — the risk in the first few months after stopping is far greater than expected from the natural course of illness, even in patients symptom-free for up to 5 years.
Key principles:
- Lithium should not be started unless there is a clear intention to continue for several years
- If stopping is necessary, taper slowly over at least 1 month, preferably 3 months
- Avoid decrements in plasma levels of >0.2 mmol/L at a time
- Even with slow taper, recurrence rates remain ~3× higher than in those who continue — this persists for many years
- Patients on high Li⁺ levels before discontinuation are particularly prone to relapse
- Abrupt discontinuation is associated with a much higher rebound risk than slow tapering
17. SPECIAL POPULATIONS
Pregnancy
- First trimester: Ebstein anomaly risk modestly elevated (~1.5–3× baseline, but baseline is very rare); benefit may outweigh risk in severe bipolar I; fetal echocardiogram if exposed
- Third trimester: Rapidly changing pharmacokinetics — increasing dose required to maintain levels as GFR rises; fetal/neonatal toxicity possible at maternal therapeutic levels (hypotonia, goiter, "floppy baby", cardiac murmur)
- Delivery: Withhold 24–48 h before; postpartum diuresis causes maternal Li⁺ to spike
- Breastfeeding: Li⁺ passes freely into breast milk; not recommended
Geriatric
- Reduced total body water + reduced creatinine clearance → narrowed safety margin
- Target lower levels: 0.6–0.8 mEq/L
- More frequent monitoring
- Compelling reason to continue: neuroprotective effects (50% reduced dementia risk)
- Avoid concurrent lisinopril
Pediatric (≥12 FDA-approved; 6–11 off-label)
- Higher Vd and GFR → shorter t½ → higher mg/kg dosing, multiple daily dosing
- Monitor renal and thyroid function as in adults
- Signs of toxicity must be reviewed with caregivers
18. CPG SYNOPSIS
CANMAT 2023 / ISBD Recommendations
- Maintenance (prophylaxis): Lithium = first-line for bipolar I and II — this position is supported by ALL major international guidelines (APA, BAP, CANMAT, NICE, WFSBP, RANZCP)
- Acute mania: First-line monotherapy (CANMAT, RANZCP); first-line for mild-moderate mania (APA, BAP); first-line combination for severe/mixed mania (APA)
- Bipolar depression: Second-line or adjunctive (less evidence than quetiapine, lurasidone)
- Monitoring: All guidelines mandate plasma Li⁺ monitoring; APA, BAP, CANMAT, NICE, RANZCP specify therapeutic ranges
Target Levels Summary (Cross-Guideline Consensus)
| Phase | Target (mEq/L or mmol/L) |
|---|---|
| Acute mania | 1.0–1.5 (never >1.2 outpatient) |
| Maintenance | 0.6–1.0 |
| Elderly maintenance | 0.6–0.8 |
| Augmentation (depression) | 0.4–0.6 |
| Toxic threshold | >1.5 |
| Dangerous | >2.0 |
| Dialysis considered | ≥5.2 (plus clinical context) |
QUICK-REFERENCE SUMMARY TABLE
| Domain | Key Facts |
|---|---|
| Class | Alkali metal ion / mood stabilizer |
| MOA | GSK-3β inhibition; inositol depletion; Na⁺ channel competition |
| Absorption | 100%; peak 30 min–2 h (IR), 4–5 h (CR) |
| Half-life | ~20 h adults; 24–36 h elderly |
| Steady state | 4–5 days (adults); 5–7+ days (elderly) |
| Protein binding | None |
| Metabolism | None |
| Excretion | 100% renal (proximal reabsorption with Na⁺) |
| Therapeutic window | 0.6–1.2 mEq/L (maintenance); 1.0–1.5 mEq/L (acute) |
| Toxic level | >1.5 mEq/L |
| Sample timing | 12-h post-dose trough |
| #1 indication | Bipolar disorder (all phases); suicide prevention |
| Key side effects | Tremor, polyuria, hypothyroidism, weight gain, CKD (long-term) |
| Most dangerous interactions | Thiazides, ACEi (esp. lisinopril), NSAIDs |
| Absolute CI | Severe renal failure, Brugada syndrome |
| Monitoring | Li⁺ + eGFR + TFTs + Ca²⁺ every 6 months |
| Taper on stopping | ≥1 month; avoid >0.2 mmol/L decrements |
Key References:
- Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th ed., Ch. 19 (Neuropharmacology)
- Katzung's Basic and Clinical Pharmacology, 16th ed., Ch. 29 (Lithium, Table 29-5/29-6)
- The Maudsley Prescribing Guidelines in Psychiatry, 15th ed., Section 2.1 (Tables 2.1, 2.2)
- CANMAT & ISBD Guidelines for Treatment of Bipolar Disorder — 2023 Update (PMID: 34599629)
- Kaplan & Sadock's Comprehensive Textbook of Psychiatry, 11th ed.Your credits are exhausted. Your daily credits reset tomorrow, or you can purchase a top-up for more.
This is a shared conversation. Sign in to Orris to start your own chat.